Continuing Medical Education Credit Information
The American College of Surgeons is accredited by the ACCME to provide continuing medical education (CME) for physicians.
AMA PRA Category 1 Credits™
The American College of Surgeons designates this enduring material for a maximum of 6 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Of the AMA PRA Category 1 Credits™ listed above, a maximum of 6 credits meet the requirements for Self-Assessment.
SESAP® Sampler is intended for general surgeons. Upon completion of SESAP Sampler annual subscription, participants should be able to assess their proficiency on questions across 12 topic areas and identify those areas that might require additional study. In addition, participants will be able to affirm existing knowledge and consider applying new knowledge to enhance their practices as appropriate. Completion of the monthly modules can be used to demonstrate a commitment to the principles of lifelong learning and self-assessment and may be useful toward fulfillment of Maintenance of Certification requirements.
Requirements to Earn 6 AMA PRA Category 1 Credits™
To be eligible for CME credit, participants must complete each of the monthly modules by answering the questions, reading the accompanying critiques, achieving a score of 100 percent (with unlimited attempts), and submitting the results online. Following completion of 12 modules, participants will complete and submit an evaluation form, after which a CME certificate will be available. The estimated time needed to complete a module and read the critiques is 30 minutes. These modules require your computer to be logged on to the Internet. Following electronic submission of the answers for 12 monthly modules and completion of an overall evaluation form, a CME certificate will be available to print. Credit will not be transferred to the participant’s MyCME Page until 12 modules have been completed.
In accordance with the ACCME Accreditation Criteria, the American College of Surgeons must ensure that anyone in a position to control the content of the educational activity has disclosed all relevant financial relationships with any commercial interest. Therefore, it is mandatory that both the program planning committee and authors complete disclosure forms. Members of the planning committee were required to disclose all financial relationships and authors were required to disclose any financial relationship as it pertains to the content of their contribution. The ACCME defines a ‘commercial interest’ as “any entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on, patients”. It does not consider providers of clinical service directly to patients to be commercial interests. The ACCME considers “relevant” financial relationships as financial transactions (in any amount) that may create a conflict of interest and occur within the 12 months preceding the time that the individual is being asked to assume a role controlling content of the educational activity.
The ACCME also requires that ACS manage any reported conflict and eliminate the potential for bias. The planning committee members and authors were contacted and the conflicts listed below have been managed to our satisfaction. However, if you perceive a bias, please advise us of the circumstances on the evaluation.
The requirement for disclosure is not intended to imply any impropriety of such relationships, but simply to identify such relationships through full disclosure, and to allow the audience to form its own judgments regarding the content.
Tawnya L. Bowles, MD, FACS (Nothing to disclose)
David R. Brenin, MD, FACS (Consultant—Insitec; Principal Investigator—Theraclion)
Clay Cothren Burlew, MD, FACS (Nothing to disclose)
Casey M. Calkins, MD, FACS (Nothing to disclose)
Jeremy W. Cannon, MD, SM, FACS (Nothing to disclose)
Jeffrey G. Chipman, MD, FACS (Nothing to disclose)
Quyen D. Chu, MD, FACS (Nothing to disclose)
Jay J. Doucet, MD, MSc, FRCSC, FACS, RDMS (Consultant honorarium—Ethicon Endo-Surgery, Inc.)
Dan Eisenberg, MD, MS, FACS (Consultant honorarium—Intuitive Surgical, Inc.)
Dina M. Elaraj, MD, FACS (Nothing to disclose)
Charles M. Friel, MD, FACS, FASCRS (Nothing to disclose)
David A. Gerber, MD, FACS (Consultant honorarium—Pathfinder Therapeutics, Inc.)
Nicole S. Gibran, MD, FACS (Principal Investigator—Mölnlycke Health Care; Principal Investigator—Fibrocell; Principal Investigator—Cytori Therapeutics, Inc.)
Kamal M. F. Itani, MD, FACS (Principal Investigator—Sanofi; Principal Investigator—Merck & Co., Inc.; Principal Investigator—Cubist Pharmaceuticals; Research Development and Advisory Board member—Davol, Inc.; Principal Investigator—Dr. Reddy’s Laboratories)
Tari A. King, MD, FACS (Nothing to disclose)
Richard P. M. Koehler, MD, FACS (Nothing to disclose)
COL Robert B. Lim, MD, FACS (Nothing to disclose)
Linda L. Maerz, MD, FACS, FCCM (Nothing to disclose)
David J. Milia, MD, FACS (Article Reviewer honorarium—Oakstone Publishing, LLC)
Forrest O. Moore, MD, FACS (Editor—Wiley-Blackwell)
Leigh A. Neumayer, MD, FACS (Nothing to disclose)
Daryl P. Pearlstein, MD, FACS (Nothing to disclose)
Walter E. Pofahl II, MD, FACS (Nothing to disclose)
Matthew B. Rossi, MD, FACS (Nothing to disclose)
Paul J. Schenarts, MD, FACS (Nothing to disclose)
David G. Sheldon, MD, FACS (Consultant—Intuitive Surgical, Inc.)
Timothy R. Siegel, MD, FACS (Nothing to disclose)
Lance E. Stuke, MD, MPH, FACS (Nothing to disclose)
William W. Turner, Jr., MD, FACS (Nothing to disclose)
J. Patrick Walker, MD, FACS (Nothing to disclose)
Travis P. Webb, MD, MHPE, FACS (Nothing to disclose)
John A. Weigelt, MD, DVM, FACS, Chair (Consultant honorarium—Pfizer, Inc.; Consultant honorarium—Astellas Pharma US, Inc.; Consultant honorarium—Decisio Health)
Richard M. Bell, MD, FACS (Nothing to disclose)
David C. Borgstrom, MD, FACS (Nothing to disclose)
David A. Bull, MD, FACS (Nothing to disclose)
Mary E. Fallat, MD, FACS (Nothing to disclose)
Jason B. Fleming, MD, FACS (Nothing to disclose)
Amy J. Goldberg, MD, FACS (Nothing to disclose)
John B. Hanks, MD, FACS (Nothing to disclose)
Lorrie A. Langdale, MD, FACS (Nothing to disclose)
Lena M. Napolitano, MD, FACS, FCCP, MCCM (Nothing to disclose)
John T. Paige, MD, FACS (Co-editor—Oxford University Press)
Timothy D. Sielaff, MD, PhD, FACS (Nothing to disclose)
David A. Spain, MD, FACS (Nothing to disclose)
James G. Tyburski, MD, FACS (Nothing to disclose)
Daniel Vargo, MD, FACS (Consultant—Allergan, Inc.)
John T. Vetto, MD, FACS (Spouse’s employer—Genentech, Inc.)
Catherine M. Wittgen, MD, FACS (Consultant and endpoint committee member—Bayer HealthCare Pharmaceuticals, Inc.; Speaker honorarium—Organogenesis Inc.)
Ajit K. Sachdeva, MD, FRCSC, FACS (Nothing to disclose)
Patrice Gabler Blair, MPH (Nothing to disclose)
Julia Dudek, MPH (Nothing to disclose)
Chrysa M. Cullather (Nothing to disclose)